Pexidartinib

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Moderate Hepatic Impairment

Conditions

Moderate Hepatic Impairment

Trial Timeline

Jan 7, 2020 → Oct 2, 2020

NCT ID

NCT04223635

About Pexidartinib

Pexidartinib is a phase 1 stage product being developed by Daiichi Sankyo for Moderate Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT04223635. Target conditions include Moderate Hepatic Impairment.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04703322	Phase 2	Active	Mar 15, 2021	May 31, 2026	Tenosynovial Giant Cell Tumor
NCT04526704	Approved	Completed	Oct 20, 2020	Jul 7, 2023	Tenosynovial Giant Cell Tumor
NCT04488822	Phase 3	Active	Sep 25, 2020	Feb 28, 2026	Tenosynovial Giant Cell Tumor
NCT04223635	Phase 1	Completed	Jan 7, 2020	Oct 2, 2020	Moderate Hepatic Impairment
NCT02734433	Phase 1	Completed	Jun 1, 2016	May 28, 2021	Advanced Solid Tumors

Competing Products

20 competing products in Moderate Hepatic Impairment

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	77
CT-P17 + EU-approved Humira	Celltrion	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
CS-3150	Daiichi Sankyo	Phase 3	77
tacrolimus	Astellas Pharma	Approved	85
Alefacept	Astellas Pharma	Approved	85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	52
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	65
Ranirestat + Placebo	Eisai	Phase 2/3	65
E6007 + Placebo	Eisai	Phase 2	52
KHK4827 + Placebo	Kyowa Kirin	Phase 3	77
KHK4827 + Placebo	Kyowa Kirin	Phase 3	77
KHK4827-Active + KHK4827-Placebo	Kyowa Kirin	Approved	85
KHK4827 + Placebo	Kyowa Kirin	Phase 2	52
Stelara + Bmab1200	Biocon	Phase 3	77
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe	Biocon	Phase 3	77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved